Abstract Purpose: Currently, there are no definite biomarkers of triple-negative breast cancer. The study aims to identify the metastasis-associated proteins of triple-negative breast tumors. Experimental Design: A murine metastatic breast cancer model has been established by using TA2 mice. Parallel proteomic analyses were done on a murine metastatic breast cancer model and its primary breast cancer using two-dimensional gel electrophoresis. The differentially expressed proteins were detected inTA2 mice developing spontaneous breast cancer and lung metastasis. Furthermore, their expression were detected in human breast cancer with or without metastasis, and their prediction values were assessed in a second set of samples. Results: Nineteen of 36 differentially expressed proteins were identified by peptide mass fingerprinting using matrix-assisted laser-desorption ionization-time of flight-mass spectrometry.These proteins were also validated in mouse tumor tissues by immunohistochemical staining. Actin, 14-3-3, vimentin, HSP70, CK18, and moesin were up-regulated in the metastatic tumors, whereas HSP90 and tubulin were absent or down-regulated. Furthermore, 61patients with triple-negative breast cancer and 39 patients with estrogen receptor-positive/progesterone receptor-positive breast cancer were selected for exploring the clinical relevance of these identified proteins to human breast cancer metastasis. Expression of 14-3-3 and HSP70 was significantly correlated with metastasis of human triple-negative breast cancer. Moreover, the validation study in the second set confirmed that 14-3-3, HSP70, and their combination had high sensitivities and specificities in predicting metastatic potential of triple-negative breast cancer. Conclusions:These tumor metastasis-associated proteins validated may be useful as biomarkers and targets for diagnosis and treatment of human triple-negative breast cancer.
Breast cancer metastasis is the main cause of treatment failure, exerting a remarkably negative effect on the cure and survival of patients suffering from breast cancer. Metastasis is a multiplestep process involving numerous genes (1, 2) . There are two distinct hypotheses regarding tumor metastasis: heterogeneous metastasis and synchronous metastasis. Heterogeneous metastasis is defined as malignant tumor cells spreading to other organs in the late stage (3) , whereas synchronous metastasis is described as tumor cells disseminating very early and evolving into metastatic disease independent from the primary tumor (4) , suggesting that protein expression in the metastatic tumor may be different from the primary tumor (5) . Therefore, the identification of metastasis protein markers in the early stage may contribute to early diagnosis and treatment of breast cancer patients with high risk of metastasis.
Triple-negative breast cancer is the subtype of invasive breast cancer with estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative phenotype, an important subtype of breast cancer due to its relationship with basal-like breast cancer. Triple-negative breast cancer is more likely to effect younger women and has a more advanced and aggressive stage. Regardless of stage at diagnosis, women with triple-negative breast cancers had poorer survival than those with other breast cancers. Bauer et al. compared 6,370 women identified as having triple-negative breast cancer with the 44,704 women with other breast cancers in United States (6) . They found that the odds of developing triple-negative breast cancer in women ages 40 <years was 1.53 times more likely than women ages 60 to 69 years. The vast majority of triplenegative breast cancers (76%) were classified as poorly differentiated or undifferentiated, whereas only 28% of the other breast cancer groups were so categorized. Because the triple-negative phenotype is not amenable to any form of endocrine therapy and has high incidence of metastasis, the patients with triple-negative breast cancer have a poor prognosis. This phenotype was significantly associated with shorter metastasis-free survival and breast cancer-specific survival even after they underwent the adjuvant anthracycline treatment. Hence, the mechanism of triple-negative breast cancer progression and metastasis and alternative chemotherapeutic regimens and/or novel therapeutic approaches need to be developed to inhibit its metastasis (7, 8) .
Mice are frequently used in genetic studies because the genetic background of many particular strains has been established. After many years, Tianjin Medical University has selected a murine spontaneous breast cancer (SBC) model from TA2 mice. The TA2 mouse strain has a high incidence of SBC without any induction by chemical stimulus (9) . Pathologic analysis showed that breast cancer cells in TA2 mice are triple negative (10, 11) .
In this study, to identify and validate the metastasisassociated proteins of triple-negative breast tumors, peripheral blood of TA2 mice with SBC were collected and engrafted into normal mice to establish a metastatic tumor model. The proteins differentially expressed between primary tumor and metastatic tumor were identified by a proteomics analysis. Furthermore, the presence of these particular metastatic-related proteins was validated in mouse tumor tissues and human breast cancer patient samples by using immunohistochemical staining.
Materials and Methods

Animals
Ten female TA2 mice with SBC (donors 1-10, D1-10) were collected. All of them were parous and the average frequency of pregnancy was 2.70 F 1.82. The average time it takes for SBC to develop is f329.81 F 95.32 days. Ten normal female mice (recipients 1-10, R1-10), 7 to 8 weeks old, received injections of peripheral blood from donors TA2 mice with SBC. All animal work was done in accordance with a protocol approved by the Institutional Animal Care and Use Committee.
Animal model bearing metastatic breast cancer Each TA2 mouse with breast cancer was anesthetized with diethyl ether and the heart was exposed. Peripheral blood was taken from the right ventricle using a heparin-treated syringe and it was injected into the abdominal cavity of R1 to R10 mice. Ninety days or so after the peripheral blood injection, ascites appeared in the mice injected with blood from D2 and D7 mice. Moreover, numerous diffuse tumor masses grew in the abdominal cavity and invaded into the abdominal wall and mesentery. The R2 and R7 celiac tumors and the D2 and D7 primary breast cancer were collected and the differentially expressed proteins were analyzed with two-dimensional electrophoresis and mass spectrometry (MS).
Two-dimensional electrophoresis
Total protein was isolated from breast cancer samples and the concentration was detected using the Bradford method. Two-dimensional electrophoresis was done using a 4700 Proteomics Discovery System according to the manufacturer's instructions (Amersham Biosciences). Aliquots (35 AL) of the denatured samples (corresponding to 1.5 mg protein) were diluted in denaturing buffer in a final volume of 170 AL. Samples were loaded on an 18 cm Ettan IPGphor apparatus (Amersham Biosciences) and samples were rehydrated overnight. The strips were then subjected to isoelectric focusing on a Multiphor apparatus using the following protocol: (a) step and hold, 500 V for 2 h; (b) gradient, 3,500 V for 5 h; and (c) hold, 3,500 V for 12 h, resulting in a total of 82 kVh. Following the isoelectric focusing, the strips were stored at -80jC.
For SDS-PAGE, the strips were equilibrated for 15 min in equilibration buffer [6 mol/L urea, 1.5 mol/L Tris-HCl (pH 8.8), 30% glycerol, 2% SDS] containing 32 mmol/L DTT followed by 15 min in equilibration buffer containing 235 mmol/L iodacetamide. The equilibrated strips were transferred to 12.5% polyacrylamide gels and overlaid with 1% agarose. The strips were subjected to electrophoresis using a Hoefer miniVE vertical electrophoresis system at 15 mA/gel for 15 h followed by 45 mA/gel until the dye front reached the ends of the gels (5 h). Gels were fixed for 1 h (50% methanol, 10% acetic acid), stained overnight with Coomassie blue G250, and then scanned with ImageMaster 2D LabScan U 5.0 (Amersham Biosciences). The spot volumes on the images were quantified with ImageMaster 2D Elite 5.0 (Amersham Biosciences), and spot matching between separate gels was visually conducted.
Analysis of the gel image. ImageMaster 2D 5.0, ImageScanner, and LabScan image collection software were used to capture, store, evaluate, and present information contained in the gel, with every sample tested three times. According to analysis by ImageMaster 2D 5.0, every sample had good reproducibility. All of the data were analyzed in SPSS 10.0 and Excel. The spots with intensity levels at least 3-fold difference between the two groups were chosen.
MS detection
Separating the sample from the gel and destaining. The differentially expressed protein spots were excised and destained. First, the gel pieces were washed in two to three changes of MQ water for 10 min each and then washed twice for 15 min each in 1:1 (v/v) water/acetonitrile and 25 mmol/L NH 4 HCO 3 . After removing all remaining liquid, enough acetonitrile was added to cover the gel pieces. After the gel pieces became white and sticky, the acetonitrile was removed.
Enzymolysis. The gel pieces were then completely dried down in a vacuum centrifuge for 30 min at 35jC followed by rehydration in freshly prepared and chilled 0.1 g/L digestion buffer containing 50 mmol/L NH 4 HCO 3 and 12.5 ng/AL trypsin. Enough digestion buffer was added to just cover the gel slices and make them swell, and the digestion buffer was removed and replaced with 20 AL of 50 mmol/L NH 4 HCO 3 . The digestion proceeded overnight at 37jC.
Matrix-assisted laser-desorption ionization-time of flight analysis, database search and identification of the protein. The peptides were extracted twice with 35 AL of 0.1% trifluoroacetic acid and 50% acetonitrile for 15 min for each extraction. The extracts were pooled and dried with nitrogen. The dry extracts were then redissolved in 3 AL of 0.1% trifluoroacetic acid and 50% acetonitrile. Sample aliquots of 0.3 AL were mixed with 0.3 AL a-cyano-4-hydroxycinnamic acid solution and then spotted on the plate. MS spectra were obtained using the ABI 4700 Proteomics Discovery System (Applied Biosystems) operating in a result-dependent acquisition mode. The MS was operated under 18 kV accelerating voltage in the reflectron mode with a m/z range of 800 to 4,000. Peak lists (S/N > 10) obtained from
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matrix-assisted laser-desorption ionization-time of flight-MS were extracted from raw data and analyzed by GPS Explorer software (version 3.5; Applied Biosystems). These data were interpreted with MASCOT (version 1.9.01; Matrix Science) and the proteins with 95% confidence interval were identified. The tandem mass spectra from the MS experiments were searched against a mouse subset database downloaded from National Center for Biotechnology Information 4 with 131,231 entries created September 15, 2006 . Search variables were the default of MASCOT. Fixed modification was carbamidomethylation of cysteines. Variable modifications were oxidation of methionine residues and phosphorylation of serine, threonine, and tyrosine residues. C-term side of KR, was cut unless next residue was P. One trypsin miscleavage was allowed. The mass accuracy was defined as <0.1 Da, the resolution should be >10, and the means of calibrating each spectrum was internal calibration. Trypsin self-digested peaks were the control to exclude contaminant ions. The resulting mass spectra were internally calibrated by using the autodigested tryptic mass values. Precursor error tolerance was set to 100 ppm and MS fragment error tolerance was set to 0.3 Da. Cutoff score/expectation value for accepting individual MS spectra was 30. Maximum peptide rank was set to 2 and minimum ion score percent confidence interval (peptide) was set to 95%. The false discovery rate was determined by selecting the option to use a ''decoy'' randomized search strategy that is available in MASCOT version 1.9.01. If peptides match to multiple members of a protein family, choose the isoforms proved to be associated with breast cancer. Western blot was done to identify the unambiguous isoforms when peptides match to multiple isoforms of a protein.
Data analysis for proteomic
Matched gel images by PDQUEST were imported into the in-house developed bioinformatics program Systematic Proteomics Laboratory Analysis and Storage Hub 5 and were analyzed statistically. Gel spots with intensity changes greater than 2.0-fold with a confidence interval above 95% (P < 0.05, two-sample t test) were considered as statistically significant changes.
Validation of metastasis-related proteins in metastastic sites of TA2 mouse and human breast cancer TA2 mouse model with spontaneous metastasis breast cancer. To see if the same markers that we identified in our peripheral blood transplant model also are expressed in the metastases of TA2 mice with spontaneous metastatic breast cancer, the primary breast cancer and the lung metastatic sites were harvested, fixed with formalin, embedded in paraffin, and in turn mounted on poly-L-lysine-coated slides. After identification of metastatic breast cancer morphologically, the expression of these proteins mentioned above was validated in the lung metastatic sites using immunohistochemical staining.
Patient samples and tissue microarray
For this study, we established two sets of breast cancer sample. In the first set, 100 breast cancer patients with detailed pathologic and clinical information were selected to compare the expression of differentially expressed proteins in breast cancer with and without metastasis. All patients underwent surgery and chemotherapy at Tianjin Cancer Hospital from 1993 to 1994. The 100 breast cancer tissues included 61 triple-negative cases and 39 ER-and PR-positive cases. The median age of all patients was 52.5 years (31-80 years). Histologic detection found that they were invasive breast cancer, and there were 58 cases with axillary nodes metastasis. The diameter of primary tumor in 5 cases was <2 cm, which in 26 cases was >5 cm, and the rest ranged from 2 to 5 cm. There were 3 cases in clinical stage I, 71 were stage II, and 26 were stage III. The follow-up was >14 years. By the end of 2007, 63 patients survived and 37 patients died for breast cancer.
In a second set, 66 independent triple-negative cases were collected for a validation study to estimate the prediction value of differentially expressed proteins. These patients underwent surgery and chemotherapy at Tianjin Cancer Hospital from 2002 to 2004, and they were triple negative identified by immunohistochemical staining. The median age of them was 48.5 years (25-92 years). They were invasive breast cancer, and 34 cases were axillary node positive. The diameter of primary tumor in 7 cases was <2 cm, which in 50 cases was >5 cm, and the rest ranged from 2 to 5 cm. There were 6 cases in clinical stage I, 48 were stage II, and 12 were stage III. The follow-up was >4 years.
Formalin-fixed, paraffin-embedded tissues from these breast cancer samples were analyzed after staining with standard H&E, and specific tissues were chosen to make a tissue microarray with 1 mm cores (1.5 mm between cores). The glass slides were purchased from Zhongshan, and the coverslips were washed in 75% alcohol and 1% hydrochloric acid before using. Immunohistochemical staining was done on the tissue microarray sections.
Immunohistochemical staining
Immunohistochemical staining was done to validate the expression of differentially expressed proteins in mouse and human spontaneous metastasis breast cancer. Sections (4 Am thick) were mounted on poly-Llysine-coated slides. Slides were deparaffinized in xylene. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in 50% methanol for 10 min at room temperature. Sections were rehydrated in alcohol, washed with PBS, and then pretreated with citrate buffer [0.01 mol/L citric acid (pH 6.0)] for 20 min at 95jC in a microwave oven. After nonspecific binding sites were blocked by exposing them to 10% normal goat serum in PBS for 20 min at 37jC, sections were incubated overnight at 4jC with rabbit polyclonal anti-vimentin (Boster Biological Technology; dilution 1:100), mouse polyclonal anti-actin (Zhongshan; ready-to-use), mouse polyclonal anti-HSP70 (Zhongshan; ready-to-use), rabbit polyclonal anti-HSP90a (Newmarker; dilution 1:200), rabbit polyclonal anti-CK18 (Maxim, Biotecho; ready-to-use), rabbit polyclonal anti-14-3-3h (Newmarker; dilution 1:200), rabbit polyclonal anti-tubulin-h (Newmarker; dilution 1:100), and mouse monoclonal anti-moesin (Newmarker; dilution 1:100). Following this incubation, the sections were rinsed with PBS and incubated with biotinylated goat anti-mouse IgG for 20 min at 37jC. The slides were then incubated with 3,3 ¶-diaminobenzidine chromogen for 5 to 10 min at room temperature and washed with distilled water. Finally, sections were slightly counterstained with hematoxylin for 1 min followed by dehydration and coverslip mounting. PBS was used in place of the primary antibodies for the negative control. The staining systems used in this study were PicTure PV6000 (Zhongshan Chemical) and Elivision Plus (Zhongshan Chemical).
Counting and statistical methods
Protein expression levels were quantified according to the method described by Zhang et al. (11) , and both the intensity and the percentage of positive cells were evaluated. More than 10 microscopic fields in one section were observed with Â400 magnification. For stain intensity, 0 was denoted for no stain, 1 was for weak positive with faint yellow, 2 was for moderate positive, and 3 was for strong positive with brown staining. Positive cells were counted in 100 tumor cells per field, 10 fields in each section. The number of positive cells was visually evaluated and cell expression was stratified as follows: 0 (negative) for <10% positive cells, 1 (weak) for <25% positive cells, 2 (moderate) for <50% positive cells, and 3 (strong) for >50% positive cells. The sum (staining index) of stain intensity and positive cell scores was used to determine the final result for each section. Statistical software SPSS 10.0 was used to evaluate the data in this study and P < 0.05 was defined as statistically significant. A rank-sum test was done to compare the difference of protein expression in the metastatic and no metastatic groups. In turn, discriminant analysis was used to establish a formula to predict the metastasis potential of triple-negative breast cancer in the second set of breast cancer samples. Single differentially expressed proteins was enforcedly entered into an independent formula. Moreover, a forward selection of stepwise discriminant analysis was done to fit a combination formula to determine which differentially expressed protein discriminate the metastasis of triple-negative breast cancer. According to the formulas, the metastasis potential of the second set of cases was predicted, and Pearson m 2 test was done to compare the difference between predicting results and actual metastasis to validate the prediction value of the differentially expressed proteins (12) .
Results
Development of SBC in TA2 mice. Seven TA2 mice developed a single tumor and the rest had multiple tumor masses. On average, 3 tumor masses were observed in a single mouse. There were 15 total tumor masses in the 10 mice that received peripheral blood injections (Fig. 1A) . When the tumor was engrafted into normal mice, the time it took for a tumor to be detected by palpation was f18 to 22 days. Under microscopy, TA2 SBC cells were arranged like glandular tubes with corpora mammillaria, lamellae, and nests, a structure similar to invasive human breast cancer (Fig. 1B) .
Establishment of celiac metastatic breast cancer. Peripheral blood (f0.8-1.5 mL), collected from each TA2 mouse with SBC, was injected into the abdominal cavities of 10 normal TA2 mice. Ninety days or so after the peripheral blood injection, the mice injected with blood from D2 and D7 developed ascites (Fig. 1C) . Tumor cells, red cells, and lymphocytes in H&E-stained sections were observed in ascitic fluid (Fig. 1D) . Moreover, numerous tumor masses appeared that were diffused into the abdominal wall and mesentery. The tumors in the abdominal cavity were engrafted into the groin of the other normal TA2 mice. Ten days later (shorter than 18-22 days above), metastatic tumors appeared in the liver, lung, kidney, and spleen, accompanied with ascites ( Fig. 1E-I) . Tumor cells had decreased cytoplasm, the nuclei were round or orbicularovate, and frequent mitoses were observed. A great many mitoses and huge tumor cells were seen in metastatic tumors in the lung, liver, and spleen. Metastatic breast cancer grew diffusely, distinct from the D2 and D7 primary breast cancer.
Identification of proteins expressed differentially in metastatic and primary breast cancer. Protein from tumors in the abdominal cavity and primary tumor were separated in triplicate using IPG-two-dimensional electrophoresis-SDS-PAGE. Isoelectric focusing in preliminary experiments was conducted with immobilized pH 3 to 10 nonlinear gradient strips. The results showed that most protein spots were located in the pH 4 to 7 range and acidic proteins were more numerous than alkaline proteins. The results of two-dimensional electrophoresis were reproducible. Four samples were separated in pH 4 to 7 and stained in parallel that ranged in molecular weight from 10 to 100 kDa. The results were analyzed with ImageMaster 2D 5.0 gel analysis software. Two hundred eighty-seven proteins were identified in primary tumor and 236 proteins were identified in metastatic tumors. There were 36 protein spots that differed >3-fold across the 2 groups and they were analyzed with MS. Thirty-six peptide mass fingerprints identified by MS were entered in the database to search their identifications. Finally, we found that, except of the repeated proteins and the proteins under the threshold, 19 proteins expressed differentially between metastatic and primary breast cancer in TA2 mice were identified (Table 1) . Compared with primary breast cancer, seven proteins such as 14-3-3 protein g, vimentin, and tropomyosin 5 were only expressed in metastatic breast cancer, whereas 3 proteins including HSP90 and peroxiredoxin 4 were absent in metastatic tumors. Actin E2 and moesin protein expression was up-regulated in the metastatic tumors, whereas tubulin and HSP70 were down- Fig. 1 . A, TA2 mouse with breast cancer is anesthetized with diethyl ether and the heart is exposed. Peripheral blood (f1mL) with tumor emboli is taken from the right ventricle using a heparin-treated syringe. Red arrow, SBC. B, tumor cells of TA2 SBC form nests or glandular tubes, with a structure similar to human invasive breast cancer. H&E, Â100. C, peripheral blood fromTA2 mice with SBC was injected into the abdominal cavity of normal mice. Ninety days or so after the injection, the mouse injected with blood from mouse 2 develops ascites. D, ascitic fluid is smeared and there are many tumor cells, red cells, and lymphocytes. H&E, Â100. E and F, metastatic tumor is engrafted into the groin of a normal TA2 mouse. Ten days later, liver and spleen swell significantly and metastatic sites are detected in the lung. Red arrow, swelling liver; blue arrow, engrafted tumor in the groin; yellow arrow, a metastatic site in the lung. G, breast cancer cells metastasize into the lung and tumor cells grow invasively around a bronchus. Red arrow, tumor cells. H&E, Â100. H, breast cancer cells metastasize into the spleen. Tumor cells invade into the spleen and the structure of the spleen is damaged. Red arrow, tumor cells. H&E, Â100. I, breast cancer cells metastasize into the liver. Tumor cells invade into the sinus hepaticus and form tumor nests. Red arrow, tumor cells. H&E, Â100.
regulated. The data suggest that the expression profile of the metastatic tumor is distinct from the primary tumor, in support of hypothesis of synchronous metastasis.
Validation of metastasis-related proteins in mouse breast cancer. To confirm whether the differentially expressed proteins identified by two-dimensional gel electrophoresis are associated with metastasis of breast cancer, the expression level of the above proteins was further evaluated in D2 and D7 primary breast cancer and R2 and R7 celiac tumor by using immunohistochemical staining. The results are shown in Fig. 2A to H. The expression of actin, 14-3-3, vimentin, HSP70, and moesin was up-regulated in metastatic breast cancer and absent or down-regulated in primary breast cancer. HSP90 and tubulin were expressed in primary breast cancer, whereas they were absent or down-regulated in metastatic breast cancer. Most breast cancer cells in the abdominal cavity were positive for vimentin, showing positive cytoplasmic staining, whereas fewer cells in primary breast cancer were weakly stained. These results are consistent with the observation by proteomics analysis. Furthermore, the expression of metastasis-related proteins confirmed in the celiac tumor was validated in the lung metastatic sites and the TA2 spontaneous primary sites. The results of immunohistochemical staining indicated that their expressions were in consistence with the proteomic results ( Fig. 2I-P) .
Clinical relevance of metastasis-related proteins to human breast cancer. To further explore the clinical relevance of these identified proteins to human breast cancer metastasis, 61 patients with triple-negative breast cancer and 39 patients with ER + /PR + breast cancer were recruited to determine if the animal model results translate to human tumors. The results showed that 14-3-3 and HSP70 expression was closely associated with breast cancer metastasis. In triple-negative breast cancer samples, the expression of 14-3-3 and HSP70 in breast cancer that developed metastasis was significantly higher than that in breast cancer that did not metastasize ( Fig. 3 ; Table 2 ; P < 0.05). The expression of other proteins was also higher than that in breast cancer without metastasize, although there were no significant difference. There was no significant difference in the expression of proteins expressed differentially between metastatic and nonmetastatic human ER + /PR + breast cancer. These results indicated that the 14-3-3 protein and HSP70 were specifically associated with metastasis of triple-negative breast cancer but not with that of ER + /PR + breast cancer. Furthermore, several prediction formula listed in Table 3 were established to predict the metastasis potential of triplenegative breast cancer using discriminant analysis. Among of them, the combination formula was fitted using stepwise method, and the 14-3-3 protein and HSP70 were identified to enter the formula. After that, a second set of triple-negative breast cancer cases was collected and stained, and the immunohistochemical stain index was substituted into the formula to predict metastasis of these cases. The results of Pearson m 2 test comparing the difference between predicting results and actual metastasis showed that the 14-3-3 protein, HSP70, their combination, and moesin had a good prediction value to triple-negative breast cancer metastasis. The sensitivities of the 14-3-3 protein, HSP70, their combination, and moesin were 88.2%, 76.5%, 47.1%, and 82.4%, respectively. The specificities of 14-3-3 and the combination of 14-3-3 and HSP70 reached 69.0% and 93.1%, respectively (Table 3) .
Discussion
Metastasis is implicated in the high mortality rate seen in breast cancer patients. Currently, there are no definite biomarkers to forecast the metastatic potential of ER -/PR -(13) and triple-negative (ER -/PR -/HER-2 -) breast cancer. Surgery accompanied with radiotherapy, chemotherapy, and biotherapy is the most successful treatment strategy for breast cancer (14, 15) . However, f40% of patients die of breast cancer recurrence and metastasis. Two features are implicated in the failure of breast cancer treatment. On one hand, tumor cells spread through blood vessels to form distinct metastases.
Evidence from numerous clinical studies shows that 70% to 80% of breast cancer patients with lymph node metastasis experience recurrence or develop metastases (16, 17) . Patients whose pathologic types, grades, and clinical stages are different have distinct risks for metastasis via blood vessels and therefore various prognoses. The other feature related to treatment failure is that some tumor cells are not sensitive to radiotherapy and chemotherapy; hence, they can survive and continue to grow and metastasize after treatment (18) . At present, the pathologic method of diagnosing breast cancer is based on the morphology of tumor cells. Using that feature alone cannot predict metastatic potential or assist in tailoring individualized treatment.
It is well known that breast cancer metastasis is a multiplestep process regulated by many genes, involving movement and migration of tumor cells, invasion into blood vessels and A to H, expression of vimentin, actin, moesin, 14-3-3, tubulin, HSP70, CK18, tubulin, and HSP90 in the primary breast cancer and metastastic tumor in the abdominal cavity. A, metastatic breast cancer cells in the abdominal cavity express high levels of vimentin and there are numerous brown granules in the cytoplasm of tumor cells. Immunohistochemistry, Â200. B, metastatic breast cancer cells express actin. Immunohistochemistry, Â200. C, metastatic breast cancer cells express moesin that is located in the cytoplasm. Immunohistochemistry, Â200. D, 14-3-3 protein expression is detected in the cytoplasm of the metastatic breast cancer cells. Immunohistochemistry, Â200. E, HSP70 protein expression is detected in the cytoplasm of the metastatic breast cancer cells. Immunohistochemistry, Â200. F, metastatic breast cancer cells express CK18. Immunohistochemistry, Â200. G, SBC cells express tubulin.Tumor cells form nests or glandular tubes. Immunohistochemistry, Â200. H, SBC cells express HSP90. Tumor cells form nests or glandular tubes. Immunohistochemistry, Â200. I to P, immunohistochemical staining for vimentin, actin, moesin, 14-3-3, tubulin, HSP70, and CK18 in the lung metastastic site of TA2 mouse with SBC. I, metastatic breast cancer cells in the lung express vimentin and brown granules are detected in the cytoplasm of some tumor cells. Immunohistochemistry, Â200. J, metastatic breast cancer cells express actin. Immunohistochemistry, Â200. K, metastatic breast cancer cells express moesin that is located in the cytoplasm. Immunohistochemistry, Â200. L, 14-3-3 protein expression is detected in the cytoplasm of the metastatic breast cancer cells. Immunohistochemistry, Â200. M, HSP70 protein expression is detected in the cytoplasm of the metastatic breast cancer cells. Immunohistochemistry, Â200. N, metastatic breast cancer cells express CK18. Immunohistochemistry, Â200. O, no significant tubulin expression in metastastic tumor cells. Immunohistochemistry, Â200. P, metastatic tumor cells are negative for HSP90 staining immunohistochemically. Immunohistochemistry, Â200. lymph vessels, and retention and adherence of tumor cells (19 -21) . Many proteins, including cell adherence molecules, members of the integrin family, proteases, cell signal transduction factors, nuclear factors, cytoskeletal proteins, cyclins, chemokines, tumor matrix proteins, growth factors, and migratory factors, take part in the process of breast cancer metastasis (22 -24) . Tumor progression to metastasis occurs through clonal genomic and epigenetic evolution. During breast cancer initiation, development, and metastasis, breast cancers not only undergo clonal growth in primary sites but also obtain the ability to disseminate to lymph nodes and other organs (20) . Metastasis that occurs in the late stage of tumor development is heterogeneous metastasis (25, 26) , whereas metastasis that occurs in the early stage is synchronous metastasis (27 -29) . The primary and metastatic tumors in synchronous metastasis share the same expression profiles, whereas the expression profile of the metastatic tumor is distinct from the primary tumor in heterogeneous metastasis. The identification of tumor metastasis biomarkers and the evaluation of breast cancer metastatic potential are the key to successful early breast cancer treatment, and their application should improve the survival rate and cure rate for breast cancer patients. Moreover, based on this idea, clinics can screen the population to determine who has a high risk for metastasis and provide targeted therapy for them. The patients with low risk can avoid undergoing blind therapy, resulting in an improvement in their quality of life (30, 31) .
The TA2 mouse strain is an inbred animal model that has a high incidence of SBC without any external stimuli. The morbidity of breast cancer in multiparous TA2 mice reaches 84.1% and the average time it takes for tumor development is f330 days. The morbidity in virginal mice is 41.4% and the average time it takes for tumor development is f450 days. Thirty-two percent of male TA2 mice also develop breast cancer and the average time it takes for tumor development is f479 days. This characteristic suggests that estrogen and progesterone play essential roles in the initiation and progression of TA2 breast cancer (10) . Immunohistochemical staining results show that SBC in the TA2 strain is triple negative, indicating that progestogen regulates breast cancer oncogenesis and development through an ER-and PR-independent pathway. Approximately one-third of women suffering from breast cancer have tumors that are positive for both ER and PR. The progression and metastasis of these breast cancers may be not associated with ER and PR (32) . In a previous study, we collected 84 TA2 mice with breast cancer. Among them, 98.8% (83 of 84) delivered more than one litter and 89.29% (75 of 84) and 5.9% (5 of 84) developed lung and liver metastases, respectively. The average time for breast cancer development was 330 days. However, it is reported that the morbidity of virginal mice is only 41.4% within an average of 450 days after birth. The SBC initiation and development in TA2 mice are highly related to the frequency of pregnancies, suggesting that progesterone may be play an important role in breast cancer initiation, progression, and maintenance of the neoplastic phenotype in the mammary gland (33) . In 1993, Kordon et al. (34) induced mammary carcinomas in BALB/c female mice using progesterone. Most of the tumors were lobular in morphology and progressively ceased to express receptors after a few in vivo passages. In mice, progestins can act as cocarcinogens together with chemical initiators, such as N-methyl-N-nitrosourea (35) and dimethylbenzanthracene (36) . Recent studies in PR knockout mice confirmed the role of PR on dimethylbenzanthracene-induced tumorigenesis (37) . There is evidence in rats that, depending on the time of carcinogen administration in relation to hormone treatment, progesterone can act as a promoter (38) .
In this study, we established a mouse model with highly metastatic breast cancer by collecting peripheral blood with tumor emboli from TA2 mice with SBC and injecting it into the abdominal cavity of normal mice. In this model, the breast cancer was readily able to proliferate and metastasize. Compared with the primary tumors, metastatic breast cancer derived from peripheral blood may express more invasion and metastasis-associated proteins. Nineteen proteins differentially expressed between metastatic and primary tumors were identified using two-dimensional electrophoresis and MS. These differentially expressed proteins may be biomarkers useful for predicting heterogeneous metastases. The expression of these differentially expressed proteins was validated with immunohistochemical staining of primary and metastatic tumors in TA2 mice. SBC in TA2 mice does not express ER or PR. Therefore, 61 triple-negative and 39 ER+/PR+ human breast cancer samples were selected to detect the relationship between the differentially expressed proteins and human breast cancer metastasis. The results showed that, in the triple-negative group, tumors developing metastases expressed more 14-3-3 and HSP70 than those without metastasis. The 14-3-3 family is a highly conserved protein family that takes part in many signal transduction pathways regulating cell proliferation, apoptosis, and differentiation. The 14-3-3 protein exerts a bridge function by regulating the activity of protein kinases and phosphorylases. Increasing evidence shows that 14-3-3 proteins play important roles in metastasis of urinary bladder tumor (39). Li et al. (40) showed highly metastatic MDA-MB-435HM cells expressed more 14-3-3 protein q than the parental MDA-MB-435 cells using two-dimensional electrophoresis and liquid chromatography-ion-trap MS. These findings suggest that 14-3-3 serves an important function in breast cancer metastasis and it may be a biomarker of breast cancer dissemination. HSP70 plays an important role in protein folding and translocation, and its expression has been shown to contribute to tumor proliferation, invasion, and metastasis. NOTE: A case is considered as metastasis when the D value is equal to 1 or >1; otherwise, it has no potential to metastasis when the D value is near to 0 or <0. Abbreviations: Se, sensitivity; FN, false-negative rate; Sp, specificity; FP, false-positive rate; YI, Youden's index; +PV, positive predictive value; -PV, negative predictive value; +LR, positive likelihood ratio; -LR, negative likelihood ratio; X, staining index.
HSP70 expression was up-regulated in breast cancer with lymph node metastasis compared with nonmetastatic tumors (41) . However, HSP90 is overexpressed in SBC in mice compared with metastatic breast cancer in mice. The significance of this difference remains unclear.
In the triple-negative group, the breast cancer cells developing metastasis expressed high levels of vimentin, suggesting that tumor cells undergo an epithelial-mesenchymal transition (42) . Actin was also expressed in the breast cancer cells developing metastasis, indicating that the metastatic cells were highly mobile (43) . Moesin was expressed in the cytoplasm of breast cancer cells with metastasis. Carmeci et al. reported that moesin is associated with the invasion and spread of ER-negative tumors (44) . Tubulin expression was reduced in the breast cancer cells developing metastasis. Tubulin is an important component of centrosomes and its function is related to mitosis and proliferation. It follows that the decreased level of tubulin facilitates tumor metastasis and it has indeed been associated with tumor grade, recurrence and metastasis (45) .
In summary, we provide evidences that the protein profile of metastatic breast cancer is different from that of primary breast cancer. Tumor invasion and metastasis-associated proteins identified and validated may be useful as biomarkers and targets for diagnosis and treatment of human triple-negative breast cancer.
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